ACTINIUM PHARMACEUTICALS ANNOUNCES ENROLLMENT IN THE RADIANZ IMAGING CLINICAL TRIAL INTENDED TO DEMONSTRATE THE PAN-CANCER POTENTIAL OF ATNM-400, A FIRST-IN-CLASS HER3-TARGETING RADIOTHERAPY

Reuters · 1d ago

Please log in to view news